Home » Stocks » EVGN

Evogene Ltd. (EVGN)

Stock Price: $3.48 USD -0.02 (-0.43%)
Updated December 1, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 123.80M
Revenue (ttm) 753,000
Net Income (ttm) -18.11M
Shares Out 35.57M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $3.48
Previous Close $3.50
Change ($) -0.02
Change (%) -0.43%
Day's Open -
Day's Range 3.48 - 3.98
Day's Volume 0
52-Week Range 0.00 - 3.98

More Stats

Market Cap 123.80M
Enterprise Value 79.90M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 35.57M
Float n/a
EPS (basic) -0.70
EPS (diluted) -0.82
FCF / Share -0.72
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 315,802
Short Ratio 0.46
Short % of Float n/a
Beta 0.32
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 164.41
PB Ratio 2.34
Revenue 753,000
Operating Income -21.17M
Net Income -18.11M
Free Cash Flow -18.57M
Net Cash 43.91M
Net Cash / Share 1.23
Gross Margin 52.05%
Operating Margin -2,810.89%
Profit Margin -2,405.30%
FCF Margin -2,465.60%
ROA -21.52%
ROE -39.50%
ROIC -54.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$8.00*
Low
8.00
Current: $3.48
High
8.00
Target: 8.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.751.753.386.5411.1314.5117.5817.0714.9012.56
Revenue Growth-56.9%-48.33%-48.3%-41.23%-23.31%-17.46%2.98%14.57%18.61%-
Gross Profit0.420.300.540.902.874.807.477.526.656.75
Operating Income-21.17-19.99-21.95-21.09-17.92-15.26-8.72-3.13-3.18-1.98
Net Income-18.11-20.76-20.84-19.59-17.21-14.53-8.88-2.520.65-6.97
Shares Outstanding25.7525.7525.6725.4425.3524.9024.0724.07--
Earnings Per Share-0.70-0.81-0.81-0.77-0.68-0.58-0.45-0.140.03-0.48
Operating Cash Flow-17.67-15.16-15.93-11.69-12.41-8.90-5.27-1.892.13-2.84
Capital Expenditures-0.90-0.37-0.59-0.80-2.01-3.56-1.61-2.93-3.75-1.40
Free Cash Flow-18.57-15.54-16.52-12.50-14.41-12.46-6.88-4.82-1.62-4.24
Cash & Equivalents46.8854.4771.7688.1610111612755.1358.79-
Total Debt2.97---------
Net Cash / Debt43.9154.4771.7688.1610111612755.1358.79-
Assets71.3658.6977.6095.9911312813764.8667.89-
Liabilities11.158.398.228.708.8411.5012.5616.6019.80-
Book Value50.1450.0569.3887.2910411612548.2648.09-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Evogene Ltd.
Country Israel
Employees 143
CEO Ofer Haviv

Stock Information

Ticker Symbol EVGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EVGN

Description

Evogene, together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.